Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

The Lancet Neurology

Volumn 9, Issue 1, 2010, Pages 119-128

  Jack Jr , Clifford R ^a   Knopman, David S ^a   Jagust, William J ^b   Shaw, Leslie M ^c   Aisen, Paul S ^d   Weiner, Michael W ^e   Petersen, Ronald C ^a   Trojanowski, John Q ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Institute on Aging   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE;

ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID; HUMAN; NERVE CELL DEGENERATION; NERVE CELL LESION; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 72049130805     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70299-6     Document Type: Note

References (115)

1. Schneider J.A., Arvanitakis Z., Bang W., and Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69 (2007) 2197-2204
2. White L., Small B.J., Petrovitch H., et al. Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. J Geriatr Psychiatry Neurol 18 (2005) 224-227
3. Knopman D.S., Parisi J.E., Salviati A., et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62 (2003) 1087-1095
4. Price J.L., and Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45 (1999) 358-368
5. Savva G.M., Wharton S.B., Ince P.G., Forster G., Matthews F.E., and Brayne C. Age, neuropathology, and dementia. N Engl J Med 360 (2009) 2302-2309
6. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J Intern Med 256 (2004) 183-194
7. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6 (2007) 734-746
8. Chetelat G., Desgranges B., de la Sayette V., Viader F., Eustache F., and Baron J.C. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 60 (2003) 1374-1377
9. Jack Jr. C.R., Petersen R.C., Xu Y.C., et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52 (1999) 1397-1403
10. Yuan Y., Gu Z.X., and Wei W.S. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment; a meta-analysis. AJNR Am J Neuroradiol 30 (2009) 404-410
11. Mattsson N., Zetterberg H., Hansson O., et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302 (2009) 385-393
12. Jagust W.J., Haan M.N., Eberling J.L., Wolfe N., and Reed B.R. Functional imaging predicts cognitive decline in Alzheimer's disease. J Neuroimaging 6 (1996) 156-160
13. Visser P.J., Verhey F., Knol D.L., et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 8 (2009) 619-627
14. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
15. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
16. Klein W.L., Stine Jr. W.B., and Teplow D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25 (2004) 569-580
17. Oddo S., Caccamo A., Tran L., et al. Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. J Biol Chem 281 (2006) 1599-1604
18. Gomez-Isla T., Hollister R., West H., et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41 (1997) 17-24
19. Bennett D.A., Schneider J.A., Wilson R.S., Bienias J.L., and Arnold S.E. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 61 (2004) 378-384
20. Terry R.D., Masliah E., Salmon D.P., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30 (1991) 572-580
21. Hampel H., Burger K., Teipel S.J., Bokde A.L., Zetterberg H., and Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 4 (2008) 38-48
22. Shaw L.M., Korecka M., Clark C.M., Lee V.M., and Trojanowski J.Q. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 6 (2007) 295-303
23. Klunk W.E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 55 (2004) 306-319
24. Rowe C.C., Ng S., Ackermann U., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 68 (2007) 1718-1725
25. 18F]FDG PET study. Neurology 68 (2007) 501-508
26. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131 (2008) 1630-1645
27. Bacskai B.J., Frosch M.P., Freeman S.H., et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol 64 (2007) 431-434
28. Rosen R.F., Ciliax B.J., Wingo T.S., et al. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol (2009) 10.1007/s00401-009-0583-3 published online Aug 19.
29. Clark C.M., Xie S., Chittams J., et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol 60 (2003) 1696-1702
30. Strozyk D., Blennow K., White L.R., and Launer L.J. CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60 (2003) 652-656
31. Schoonenboom N.S., van der Flier W.M., Blankenstein M.A., et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging 29 (2008) 669-675
32. 42 in humans. Ann Neurol 59 (2006) 512-519
33. Jagust W.J., Landau S.M., Shaw L.M., et al. Relationships between biomarkers in aging and dementia. Neurology 73 (2009) 1193-1199
34. Grimmer T., Riemenschneider M., Forstl H., et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65 (2009) 927-934
35. 18F-FDDNP binding. J Nucl Med 50 (2009) 1464-1470
36. Buerger K., Ewers M., Pirttila T., et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129 (2006) 3035-3041
37. Shaw L.M., Vanderstichele H., Knapik-Czajka M., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65 (2009) 403-413
38. Hesse C., Rosengren L., Andreasen N., et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297 (2001) 187-190
39. Ost M., Nylen K., Csajbok L., et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67 (2006) 1600-1604
40. Arai H., Terajima M., Miura M., et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 38 (1995) 649-652
41. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., and Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol 26 (1995) 231-245
42. Tapiola T., Overmyer M., Lehtovirta M., et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 8 (1997) 3961-3963
43. Bian H., Van Swieten J.C., Leight S., et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70 (2008) 1827-1835
44. Grossman M., Farmer J., Leight S., et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 57 (2005) 721-729
45. Ballatore C., Lee V.M., and Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8 (2007) 663-672
46. Schwartz W.J., Smith C.B., Davidsen L., et al. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science 205 (1979) 723-725
47. Attwell D., and Laughlin S.B. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 21 (2001) 1133-1145
48. Rocher A.B., Chapon F., Blaizot X., Baron J.C., and Chavoix C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage 20 (2003) 1894-1898
49. Jagust W., Reed B., Mungas D., Ellis W., and Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 69 (2007) 871-877
50. Ibanez V., Pietrini P., Alexander G.E., et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 50 (1998) 1585-1593
51. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., and Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42 (1997) 85-94
52. Hoffman J.M., Welsh-Bohmer K.A., Hanson M., et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 41 (2000) 1920-1928
53. Petrie E.C., Cross D.J., Galasko D., et al. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol 66 (2009) 632-637
54. Bobinski M., de Leon M.J., Wegiel J., et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 95 (2000) 721-725
55. Jack Jr. C.R., Petersen R.C., O'Brien P.C., and Tangalos E.G. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 42 (1992) 183-188
56. Fox N.C., Scahill R.I., Crum W.R., and Rossor M.N. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 52 (1999) 1687-1689
57. Jack Jr. C.R., Dickson D.W., Parisi J.E., et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 58 (2002) 750-757
58. Silbert L.C., Quinn J.F., Moore M.M., et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 61 (2003) 487-492
59. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82 (1991) 239-259
60. Whitwell J.L., Josephs K.A., Murray M.E., et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 71 (2008) 743-749
61. Ingelsson M., Fukumoto H., Newell K.L., et al. Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62 (2004) 925-931
62. Jack Jr. C.R., Lowe V.J., Weigand S.D., et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132 (2009) 1355-1365
63. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67 (2006) 446-452
64. Aizenstein H.J., Nebes R.D., Saxton J.A., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65 (2008) 1509-1517
65. Peskind E.R., Li G., Shofer J., et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 63 (2006) 936-939
66. Bouwman F.H., Schoonenboom N.S., Verwey N.A., et al. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 30 (2009) 1895-1901
67. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., and Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64 (2007) 343-349
68. Fagan A.M., Head D., Shah A.R., et al. Decreased cerebrospinal fluid Aβ(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65 (2009) 176-183
69. 42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69 (2007) 631-639
70. Gustafson D.R., Skoog I., Rosengren L., Zetterberg H., and Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 78 (2007) 461-464
71. Stomrud E., Hansson O., Blennow K., Minthon L., and Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 24 (2007) 118-124
72. Braak H., and Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18 (1997) 351-357
73. Chetelat G., Desgranges B., De La Sayette V., Viader F., Eustache F., and Baron J.C. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport 13 (2002) 1939-1943
74. Ewers M., Buerger K., Teipel S.J., et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 69 (2007) 2205-2212
75. Sluimer J.D., Bouwman F.H., Vrenken H.P., et al. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging (2008) 10.1016/j.neurobiolaging.2008.06.016 published online Aug 7.
76. 18F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 98 (2001) 10966-10971
77. Jagust W., Gitcho A., Sun F., Kuczynski B., Mungas D., and Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol 59 (2006) 673-681
78. Fox N.C., Warrington E.K., and Rossor M.N. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet 353 (1999) 2125
79. Jack Jr. C.R., Shiung M.M., Gunter J.L., et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62 (2004) 591-600
80. Kaye J.A., Swihart T., Howieson D., et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 48 (1997) 1297-1304
81. Engler H., Forsberg A., Almkvist O., et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129 (2006) 2856-2866
82. Josephs K.A., Whitwell J.L., Ahmed Z., et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 63 (2008) 204-212
83. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131 (2008) 665-680
84. Mormino E.C., Kluth J.T., Madison C.M., et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132 (2009) 1310-1323
85. Frisoni G.B., Lorenzi M., Caroli A., Kemppainen N., Nagren K., and Rinne J.O. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 72 (2009) 1504-1511
86. De Santi S., de Leon M.J., Rusinek H., et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22 (2001) 529-539
87. Reiman E.M., Uecker A., Caselli R.J., et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol 44 (1998) 288-291
88. Vemuri P., Wiste H.J., Weigand S.D., et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73 (2009) 287-293
89. Sunderland T., Wolozin B., Galasko D., et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry 46 (1999) 750-755
90. Bouwman F.H., van der Flier W.M., Schoonenboom N.S., et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 69 (2007) 1006-1011
91. Vemuri P., Wiste H.J., Weigand S.D., et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 73 (2009) 294-301
92. Fox N.C., and Freeborough P.A. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J Magn Reson Imaging 7 (1997) 1069-1075
93. Chan D., Janssen J.C., Whitwell J.L., et al. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet 362 (2003) 1121-1122
94. Ridha B.H., Barnes J., Bartlett J.W., et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 5 (2006) 828-834
95. Wahlund L.O., and Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 339 (2003) 99-102
96. Whitwell J.L., Przybelski S.A., Weigand S.D., et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 130 (2007) 1777-1786
97. Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord 20 suppl 2 (2006) S69-S74
98. Nelson P.T., Abner E.L., Schmitt F.A., et al. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol (2008) 10.1111/j.1750-3639.2008.00244.x published online Nov 19.
99. 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008) 216-223
100. Petersen R.C. Alzheimer's disease: progress in prediction. Lancet Neurol 9 (2010) 4-5
101. 11C]PIB-PET study. Neurobiol Dis 32 (2008) 412-419
102. Ross B.D., Bluml S., Cowan R., Danielsen E., Farrow N., and Tan J. In vivo MR spectroscopy of human dementia. Neuroimaging Clin N Am 8 (1998) 809-822
103. Duyckaerts C., and Hauw J.J. Prevalence, incidence and duration of Braak's stages in the general population: can we know?. Neurobiol Aging 18 (1997) 362-369 89-92.
104. Corder E.H., Saunders A.M., Strittmatter W.J., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
105. Reiman E.M., Chen K., Alexander G.E., et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 101 (2004) 284-289
106. Scarmeas N., Habeck C.G., Stern Y., and Anderson K.E. APOE genotype and cerebral blood flow in healthy young individuals. JAMA 290 (2003) 1581-1582
107. Ghebremedhin E., Schultz C., Braak E., and Braak H. High frequency of apolipoprotein E ε4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp Neurol 153 (1998) 152-155
108. Reiman E.M., Chen K., Liu X., et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 106 (2009) 6820-6825
109. Roses A.D. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol 53 (1994) 429-437
110. Drzezga A., Grimmer T., Henriksen G., et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72 (2009) 1487-1494
111. Harold D., Abraham R., Hollingworth P., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41 (2009) 1088-1093
112. Lambert J.C., Heath S., Even G., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41 (2009) 1094-1099
113. Buckner R.L., Snyder A.Z., Shannon B.J., et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25 (2005) 7709-7717
114. Sperling R.A., Laviolette P.S., O'Keefe K., et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63 (2009) 178-188
115. Buckner R.L., Sepulcre J., Talukdar T., et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci 29 (2009) 1860-1873